Posted by admin on May 21st, 2022

Wall Street brokerages predict that LeMaitre Vascular, Inc. (NASDAQ:LMAT – Get Rating) will post $41.26 million in sales for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for LeMaitre Vascular’s earnings, with estimates ranging from $41.10 million to $41.69 million. LeMaitre Vascular reported sales of $40.67 million in the same quarter last year, which indicates a positive year over year growth rate of 1.5%. The firm is scheduled to announce its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that LeMaitre Vascular will report full-year sales of $162.51 million for the current year, with estimates ranging from $162.00 million to $163.20 million. For the next year, analysts anticipate that the firm will report sales of $172.75 million, with estimates ranging from $170.01 million to $175.14 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that that provide coverage for LeMaitre Vascular.

LeMaitre Vascular (NASDAQ:LMAT – Get Rating) last released its quarterly earnings results on Thursday, April 28th. The medical instruments supplier reported $0.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.28 by ($0.01). LeMaitre Vascular had a return on equity of 11.41% and a net margin of 17.09%. The firm had revenue of $39.56 million for the quarter, compared to analyst estimates of $38.65 million. During the same period last year, the firm earned $0.28 EPS. The company’s quarterly revenue was up 10.2% compared to the same quarter last year.

LMAT has been the subject of a number of research reports. StockNews.com initiated coverage on LeMaitre Vascular in a report on Thursday, March 31st. They set a “hold” rating for the company. Zacks Investment Research lowered LeMaitre Vascular from a “buy” rating to a “sell” rating in a research report on Tuesday, May 3rd. Finally, Barrington Research cut their target price on LeMaitre Vascular from $54.00 to $50.00 in a research report on Friday, April 29th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $57.00.

In other LeMaitre Vascular news, insider Trent G. Kamke sold 7,929 shares of the firm’s stock in a transaction that occurred on Wednesday, March 2nd. The stock was sold at an average price of $48.22, for a total value of $382,336.38. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 12.50% of the company’s stock.

Several institutional investors have recently made changes to their positions in the stock. Captrust Financial Advisors increased its position in LeMaitre Vascular by 555.3% during the first quarter. Captrust Financial Advisors now owns 616 shares of the medical instruments supplier’s stock worth $29,000 after buying an additional 522 shares during the last quarter. Point72 Hong Kong Ltd bought a new position in shares of LeMaitre Vascular in the 3rd quarter valued at $54,000. O Shaughnessy Asset Management LLC lifted its stake in shares of LeMaitre Vascular by 827.8% in the 3rd quarter. O Shaughnessy Asset Management LLC now owns 1,336 shares of the medical instruments supplier’s stock valued at $71,000 after acquiring an additional 1,192 shares during the last quarter. Hardy Reed LLC acquired a new stake in LeMaitre Vascular in the first quarter valued at $91,000. Finally, Quantbot Technologies LP acquired a new stake in LeMaitre Vascular during the 1st quarter worth about $175,000. 84.90% of the stock is owned by institutional investors and hedge funds.

LMAT opened at $44.80 on Friday. The stock has a market capitalization of $983.45 million, a price-to-earnings ratio of 35.84, a price-to-earnings-growth ratio of 3.47 and a beta of 1.29. The business has a 50-day moving average of $44.89 and a two-hundred day moving average of $46.51. LeMaitre Vascular has a 12 month low of $38.32 and a 12 month high of $64.50.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 2nd. Investors of record on Tuesday, May 17th will be paid a $0.125 dividend. This represents a $0.50 annualized dividend and a yield of 1.12%. The ex-dividend date is Monday, May 16th. LeMaitre Vascular’s dividend payout ratio is currently 40.00%.

About LeMaitre Vascular (Get Rating)

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system.

Get a free copy of the Zacks research report on LeMaitre Vascular (LMAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.

$13.92 Million in Sales Expected for Minerva Surgical, Inc. (NASDAQ:UTRS) This Quarter

ON (NYSE:ONON) Upgraded by Zacks Investment Research to “Hold”